TwitterRSSFacebookDirectors Blog
  Disorders A - Z:   A    B   C    D    E    F    G    H    I    J    K    L    M    N    O    P    Q    R    S    T    U    V    W    X    Y    Z

You Are Here: Home  »  Disorders A - Z  »  Learning Disabilities  » 

Skip secondary menu

Learning Disabilities Press Releases

Blueprint Neurotherapeutics logo

NIH launches neurological drug development projects
Wednesday, Jul 31, 2013
The National Institutes of Health has launched three innovative projects that will focus on development of therapeutics for Fragile X syndrome, nicotine addiction, and age-related macular degeneration (AMD). These projects are funded through the NIH Blueprint Neurotherapeutics Network which provides access to a variety of drug development resources.

DCDC2: Demystifying and Decoding Dyslexia
Tuesday, Feb 28, 2006
A recent study shows that variations in a gene called DCDC2 may disrupt the normal formation of brain circuits that are necessary for fluent reading, leading to dyslexia. After further research, genetic screening for these variations could identify affected children early in their lives and possibly prevent the misdiagnosis of other learning disabilities that resemble dyslexia.

Genetic Analysis of Childhood Brain Tumors Improves Diagnosis And Predicts Survival
Friday, Mar 8, 2002
Doctors who treat brain tumors and other kinds of cancer have long struggled to understand why some patients respond well to therapy while others do not. In recent years, it has become clear that the answer lies at least partially in the genes. Two studies now show that identifying the "genetic fingerprints" of some childhood brain tumors can greatly improve diagnosis and predict patients' long-term survival. The findings help researchers understand how the tumors develop and may lead to improved ways of treating them.
Fact Sheet

Researchers Identify Potential Treatment for Learning Disability in Neurofibromatosis
Wednesday, Jan 16, 2002
Researchers studying learning disabilities associated with neurofibromatosis type 1, or NF1, have traced the problem to excessive activity of a crucial signaling molecule and have successfully reversed the disabilities in mice by giving them an experimental drug. The findings provide hope that these learning problems may one day be treatable in humans.
Fact Sheet